Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Tech Journal of Colorado.
Press releases published on April 9, 2025
Le PDG de Tritium annonce une solution révolutionnaire de recharge rapide en CC qui sera dévoilée à l’ACT Expo
GlobeNewswire
·
April 9, 2025
LEBANON, Tennessee, 09 avr. 2025 (GLOBE NEWSWIRE) -- Tritium, l’un des leaders mondiaux des chargeurs rapides à courant continu (CC) pour véhicules électriques (VE), a annoncé aujourd’hui qu’il dévoilerait une architecture révolutionnaire de recharge …
Context Therapeutics Doses First Patient in Phase 1 Clinical Trial of CT-95
GlobeNewswire
·
April 9, 2025
CT-95 is a mesothelin x CD3 T cell engaging bispecific antibody CT-95 is Context’s second T cell engaging bispecific antibody to enter the clinic in 2025 PHILADELPHIA, April 09, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or “Company”) ( …
Amarin Confirms Effective Date for 1-For-20 ADS Ratio Change
GlobeNewswire
·
April 9, 2025
DUBLIN and BRIDGEWATER, N.J., April 09, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), today confirmed that April 11, 2025 will be the effective date for the Company’s previously announced Ratio Change on its American Depositary Shares (“ …
Theratechnologies Reports Financial Results for the First Quarter 2025 and Reviews Key Achievements
GlobeNewswire
·
April 9, 2025
FDA Approves EGRIFTA WR™ (Tesamorelin F8) to Treat Excess Visceral Abdominal Fat in Adults with HIV and Lipodystrophy Total Revenue $19 million, representing +17% growth year over year FDA Approves Prior Approval Supplement (PAS) for EGRIFTA SV® sBLA …
Theratechnologies présente ses résultats financiers pour le premier trimestre de 2025 et passe en revue ses principales réalisations
GlobeNewswire
·
April 9, 2025
La FDA approuve EGRIFTA WRMC (la formulation F8 de la tésamoréline) pour traiter l’excès de graisse viscérale abdominale chez les adultes vivant avec le VIH atteints de lipodystrophie Les revenus totaux s’élèvent à 19 millions de dollars, en hausse de 17 % …
Balko Technologies Enters into Agreement with Draganfly for Integration of Advanced Modular LiDAR Drone Solutions; Multiple Orders Placed
GlobeNewswire
·
April 9, 2025
Tampa, FL, April 09, 2025 (GLOBE NEWSWIRE) -- Draganfly Inc. (NASDAQ: DPRO) (“Draganfly” or the “Company”), an industry-leading developer of drone solutions and systems, is pleased to have been selected as the primary UAS provider by Balko Technologies, an …
Authentrics.ai Launches AI Machine-Learning Resilience Infrastructure on Google Cloud, Empowering AI Governance and Trust at Scale
GlobeNewswire
·
April 9, 2025
LAS VEGAS, April 09, 2025 (GLOBE NEWSWIRE) -- Today Authentrics.ai, an innovator in frontier AI trust and reliability, announced the launch of its Machine-Learning Resilience Infrastructure (MRI) software for the Google Cloud Platform. This release marks a …
Preliminary results for the year ended 31 December 2024
GlobeNewswire
·
April 9, 2025
~ Strong commercial momentum underpins transformative financial performance ~ Strong 2024 financial performance in line with guidance Revenue growth of 44% to £128.8 million compared to 2023, organic revenue growth of 81%1 Operating EBITDA2 loss of £(15.3) …
Climb Channel Solutions Recognizes Freshworks as Strategic Partner of the Year at 2025 Climb Partner Conference
GlobeNewswire
·
April 9, 2025
EATONTOWN, N.J., April 09, 2025 (GLOBE NEWSWIRE) -- Climb Channel Solutions, an international specialty technology distributor and wholly owned subsidiary of Climb Global Solutions, Inc. (NASDAQ: CLMB) proudly honored Freshworks with the Strategic Partner …
Atea Pharmaceuticals Announces Dosing of First Patient in C-BEYOND, Phase 3 Study Evaluating Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus
GlobeNewswire
·
April 9, 2025
Regimen has Potential Best-in-Class Profile with Short Treatment Duration, Low Risk for Drug-Drug Interactions and Convenience with No Food Effect HCV Infection Remains a Significant Global Health Burden, with Approximately 50 Million People Infected, …
Aquestive Therapeutics to Participate in Piper Sandler Spring Biopharma Symposium
GlobeNewswire
·
April 9, 2025
WARREN, N.J., April 09, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and …
Lantronix Ranks 8th on Orange County Business Journal’s List of Fastest-Growing Midsize Public Companies
GlobeNewswire
·
April 9, 2025
IRVINE, Calif., April 09, 2025 (GLOBE NEWSWIRE) -- Lantronix Inc. (NASDAQ: LTRX), a global leader of compute and connectivity for IoT solutions enabling Edge AI Intelligence, today announced it has been named the 8th Fastest-Growing Midsize Public Company …
Tonix Pharmaceuticals and Makana Therapeutics Announce Collaboration Combining Tonix’s Anti-CD40L Monoclonal Antibody (TNX-1500) with Makana’s Genetically Engineered Organs in Preclinical and Clinical Xenotransplantation Studies
GlobeNewswire
·
April 9, 2025
Agreement includes the use of Tonix’s TNX-1500, as part of an immunomodulatory regimen to reduce rejection of Makana’s genetically engineered pig organs in xenotransplantation Establishes framework for Makana’s kidney, heart and islet cell programs to …
Kymera Therapeutics Appoints Noah Goodman as Chief Business Officer
GlobeNewswire
·
April 9, 2025
WATERTOWN, Mass., April 09, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced the …
KSQ Therapeutics Announces First Patient Dosed in Phase 1/2 Study for KSQ-004EX, a CRISPR/Cas9-Engineered Tumor Infiltrating Lymphocyte (eTIL®) Therapy
GlobeNewswire
·
April 9, 2025
LEXINGTON, Mass., April 09, 2025 (GLOBE NEWSWIRE) -- KSQ Therapeutics, Inc. (KSQ), a clinical-stage biotechnology company developing treatments for solid tumors, today announced the first patient dosed in the Phase 1/2 clinical study of KSQ-004EX, a novel …
ANI Pharmaceuticals to Discuss First Quarter 2025 Financial Results on May 9, 2025, at 8:00 a.m. ET
GlobeNewswire
·
April 9, 2025
PRINCETON, N.J., April 09, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company will release its first quarter 2025 financial results on Friday, May 9, 2025, prior to the market open. …
Orion publishes Interim Report for January–March 2025 and holds a webcast on 23 April 2025
GlobeNewswire
·
April 9, 2025
ORION CORPORATION PRESS RELEASE 9 APRIL 2025 at 13.30 EEST Orion publishes Interim Report for January–March 2025 and holds a webcast on 23 April 2025 Orion will publish Interim Report for January–March 2025 on Wednesday, 23 April 2025 at …
Orion julkaisee osavuosikatsauksen 1–3/2025 ja järjestää verkkolähetyksen 23.4.2025
GlobeNewswire
·
April 9, 2025
ORION OYJ LEHDISTÖTIEDOTE 9.4.2025 KLO 13.30 Orion julkaisee osavuosikatsauksen 1–3/2025 ja järjestää verkkolähetyksen 23.4.2025 Orion julkaisee osavuosikatsauksen 1–3/2025 keskiviikkona 23.4.2025 noin klo 12.00. Tiedote ja siihen …
DIAGNOS Provides Update on its Health Canada Medical Device Licence Application
GlobeNewswire
·
April 9, 2025
BROSSARD, Quebec, April 09, 2025 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a pioneer in early detection of certain ophthalmic health issues using advanced technology based on Artificial …
DIAGNOS fait le point sur sa demande d'homologation d'un instrument médical auprès de Santé Canada
GlobeNewswire
·
April 9, 2025
BROSSARD, Québec, 09 avr. 2025 (GLOBE NEWSWIRE) -- Diagnos inc. (« DIAGNOS » ou la « Société ») (Bourse de croissance TSX : ADK, OTCQB : DGNOF, FWB : 4D4A), un pionnier de la détection précoce de certains problèmes de santé ophtalmique à l'aide d'une …